14 completed, 5 recruiting, 4 not yet recruiting. 10 Phase 2, 4 Phase 1, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 4, Not yet recruiting 4, Recruiting 2 |
| Phase 1 | 4 | Completed 4 |
| Not applicable | 2 | Completed 1, Recruiting 1 |
Follow Primary Sclerosing Cholangitis (PSC): new trials by email Literature Review of Primary Sclerosing Cholangitis (PSC) trials Research Report on Primary Sclerosing Cholangitis (PSC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vancomycin Efficacy in Response to Dysbiosis in Atypical Colitis Oral Vancomycin - Ulcerative Colitis (UC), Primary Sclerosing Cholangitis (PSC) | Phase 2 | Not yet recruiting | Tampere University Hospital | 140 | 2026-10-01 | 2026-09-10 |
| Investigation of Vancomycin Efficacy in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis Placebo (blinded), Vancomycin (blinded), Vancomycin (open-label extension) - Ulcerative Colitis (UC), Primary Sclerosing Cholangitis (PSC) | Phase 2 | Recruiting | McMaster University | 14 | 2026-06-17 | 2026-10-09 |
| The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching Upadacitinib 15 MG - Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC) | Phase 2 | Not yet recruiting | RenJi Hospital | 44 | 2026-06-01 | 2026-07-01 |
| Fecal Microbiota Transplantation for Primary Sclerosing Cholangitis - Randomized Study Versus Sham Transplantation Fecal microbiota transplantation (FMT), Sham-transplantation (placebo) - Primary Sclerosing Cholangitis (PSC), Inflammatory Bowel Disease (IBD) | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 72 | 2026-05-01 | 2026-03-17 |
| Biodegradable Stents in Primary Sclerosing Cholangitis archimedes stent - Primary Sclerosing Cholangitis (PSC) | Not applicable | Recruiting | King's College Hospital NHS Trust | 20 | 2026-03-01 | 2026-05-29 |
| A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC LB-P8 low-dose, LB-P8 high-dose, Placebo - Primary Sclerosing Cholangitis (PSC) | Phase 2 | Recruiting | LISCure Biosciences | 87 | 2025-11-01 | 2025-10-24 |
| Efficacy and Safety of HK-660S in the Treatment of Primary Sclerosing Cholangitis HK-660S 100mg, HK-660S 200mg, Placebo - Primary Sclerosing Cholangitis (PSC) | Phase 2 | Not yet recruiting | CuromeBiosciences | 105 | 2025-08-18 | 2025-05-16 |
| S-adenosylmethionine (SAMe) in Patients With Primary Sclerosing Cholangitis (PSC) S-Adenosyl-L-methionine (SAMe), Placebo - Primary Sclerosing Cholangitis (PSC) | Not applicable | Completed | Medical University of Warsaw | 60 | 2023-09-01 | 2026-08-25 |
| Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159 CS0159 - Primary Sclerosing Cholangitis (PSC) | Phase 1 | Completed | Cascade Pharmaceuticals, Inc | 79 | 2021-10-26 | 2022-10-18 |
| Endoscopy and Primary Sclerosing Cholangitis Endoscopic Retrogradade CholangioPancreatography (ERCP) - Primary Sclerosing Cholangitis (PSC) | Completed | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 118 | 2021-07-01 | 2024-11-14 | |
| Deciphering the Self-antigen Specific T Cell Signature of Autoimmune Liver Diseases Autoimmune Hepatitis, Primary Biliary Cholangitis (PBC) | Completed | Nantes University Hospital | 220 | 2021-04-20 | 2026-09-01 | |
| Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects CM-101, Placebo - Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC) | Phase 1 | Completed | ChemomAb Ltd. | 8 | 2019-03-05 | 2023-09-14 |
| Cholangioscopy in Primary Sclerosing Cholangitis (PSC) SpyGlass DS I - II - Primary Sclerosing Cholangitis (PSC) | Completed | Boston Scientific Corporation | 43 | 2018-12-06 | 2023-01-25 | |
| A POC and Dose-Ranging Study of HTD1801 in PSC Patients HTD1801, Placebo - Primary Sclerosing Cholangitis (PSC) | Phase 2 | Completed | HighTide Therapeutics (Hong Kong) Limited | 59 | 2018-02-09 | 2026-08-25 |
| Swiss Primary Sclerosing Cholangitis Cohort Study Cholangitis, Sclerosing, PSC | Recruiting | Fondazione Epatocentro Ticino | 120 | 2017-02-28 | 2025-08-19 | |
| Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function Cilofexor - Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC) | Phase 1 | Completed | Gilead Sciences | 57 | 2016-07-13 | 2021-01-07 |
| Spanish Registry of Autoimmune and Cholestatic Liver Diseases (ColHai) Hepatitis Autoimmune Disease, Primary Biliary Cholangitis (PBC) | Recruiting | Asociación Española para el Estudio del Hígado | 5000 | 2016-01-01 | 2025-01-10 | |
| Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC) Obeticholic Acid (OCA), Placebo - Primary Sclerosing Cholangitis (PSC) | Phase 2 | Completed | Intercept Pharmaceuticals | 77 | 2015-02-09 | 2021-07-08 |
| Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis LUM001 - Primary Sclerosing Cholangitis (PSC) | Phase 2 | Completed | Mirum Pharmaceuticals, Inc. | 27 | 2014-03-01 | 2019-03-29 |
| Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC) Simtuzumab, Placebo - Primary Sclerosing Cholangitis (PSC) | Phase 2 | Completed | Gilead Sciences | 235 | 2013-03-04 | 2019-10-22 |
Showing 20 of 23. Sign in to see all of them.
Cholangitis, Sclerosing (23) · Inflammatory Bowel Diseases (3) · Liver Cirrhosis, Biliary (3) · Cholangiocarcinoma (2) · Colitis, Ulcerative (2) · Digestive System Diseases (2) · Non-alcoholic Fatty Liver Disease (2) · Pruritus (2) · Alagille Syndrome (1) · Bile Duct Diseases (1) · Biliary Tract Diseases (1) · Cholangitis (1) · Cholestasis (1) · Colitis (1) · Colonic Diseases (1)
Bile Duct Diseases (22) · Biliary Tract Diseases (22) · Cholangitis (22) · Digestive System Diseases (21) · Gastroenteritis (5) · Liver Diseases (5) · Pathological Conditions, Signs and Symptoms (5) · Fibrosis (4) · Gastrointestinal Diseases (4) · Intestinal Diseases (4) · Pathologic Processes (4) · Cholestasis (3) · Cholestasis, Intrahepatic (3) · Liver Cirrhosis (3) · Skin Diseases (3)
Vancomycin (2) · Fecal Microbiota Transplantation (1) · Genetic Testing (1) · Rifaximin (1) · S-Adenosylmethionine (1) · cilofexor (1) · obeticholic acid (1) · simtuzumab (1) · streptococcal polysaccharide type III group B (1) · upadacitinib (1)
Gilead Sciences (2) · Mayo Clinic (2) · Asociación Española para el Estudio del Hígado (1) · Assistance Publique - Hôpitaux de Paris (1) · Boston Scientific Corporation (1) · Cascade Pharmaceuticals, Inc (1) · ChemomAb Ltd. (1) · CuromeBiosciences (1) · Exact Sciences Corporation (1) · Fondazione Epatocentro Ticino (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · HighTide Therapeutics (Hong Kong) Limited (1) · Intercept Pharmaceuticals (1) · King's College Hospital NHS Trust (1) · LISCure Biosciences (1)
United States (11) · Canada (6) · Italy (3) · United Kingdom (3) · France (2) · Netherlands (2) · Spain (2) · Belgium (1) · China (1) · Denmark (1) · Finland (1) · Germany (1) · Israel (1) · New Zealand (1) · Norway (1)
Adrian Di Bisceglie, MD,FACP,FAASLD (1) · Andrea Tringali, MD, PhD (1) · Arnon Aharon, MD (1) · Christopher Bowlus, MD, PhD (1) · Cyriel Ponsioen, MD, PhD (1) · Douglas Adler, MD (1) · George Harb, MD (1) · Jayant Talwalkar, MD (1) · Johannes Eksteen, MD, PhD (1) · Kathleen Doisy, MD (1) · Konstantinos N Lazaridis, M.D. (1) · Lars Aabakken, MD, PhD (1)
PMID 21134112, PMID 24914504, PMID 30153359, PMID 32165251, PMID 36327436, PMID 37184523, PMID 38967589, PMID 39424872, PMID 39880819, PMID 39996122, PMID 42271063
2014 (2), 2023 (1), 2025 (1)